Like most point mutations, the majority are probably mildly deleterious.
Even though a considerable number of PRKN mutations are dosage mutations, the majority are sequence variants, hence, we decided to perform the initial screen of our cohort only for these variants.
Of these mutations, the majority (7, 34, 44, 22, and 18, respectively for viruses from R1 R5) were in predicted recipient-HLA-restricted epitopes, of which respectively 2, 10, 12, 6 and 8 were at anchor residue positions.
During the first 2 3 weeks after transmission, viruses from recipients R1 to R5 showed 7, 1, 5, 4, and 9 forward mutations, the majority of which in predicted recipient-HLA-restricted CTL epitopesb (Figure 1, right panel, black stacks).
Sequencing of the region containing Y2 I-AniI target site from cells having lost GFP expression revealed a series of genetic mutations, the majority being small deletions (64.9%≤30 bp), with a lesser number of larger deletions (4%, some over 200 bp); insertions (8.1%) or a combination of insertion/deletions (10.8%) (Fig. 4d, GenBank accession numbers: HQ416600 to HQ416674).
For EGFRvIII and other deletion mutations, the majority of cases expressed levels below background.
Interestingly, the G34 mutations, the K36M mutations, and the majority of K27M mutations occur in genes encoding the replacement histone H3.3.
Despite the increased frequency of mutation, the R882 mutations comprised the majority of DNMT3a mutations and were associated with a significantly worse prognosis.
The mutational analysis showed that among the 45 cases with a TP53 mutation, the majority exhibited differences between DNA and cDNA sequencing (66.7%).
However, among the patients with drug resistance mutation, the majority were observed in patients with the age of greater than 25 years (Tables 3 and 5).
When asked how certain they are about having a BRCA1/2 mutation the majority (75%) were uncertain, 22% were certain, and 3% certain that they did not.
